ProMIS Neurosciences Inc. (PMN) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
SUITE 200, 1920 YONGE STREET TORONTO, ON M4S 3E2 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 3/31/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 13,324,218 | 12,630,504 | 5,906,805 | |||
| Cash and cash equivalent | 13,291,167 | 12,598,146 | 5,875,796 | |||
| Short-term investments | 33,051 | 32,358 | 31,009 | |||
| Prepaid expense | 383,257 | 509,309 | 547,337 | |||
| Other undisclosed current assets | 5,203,981 | 479,332 | 449,345 | |||
| Total current assets: | 18,911,456 | 13,619,145 | 6,903,487 | |||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 321 | |||||
| Intangible assets, net (including goodwill) | 20,838 | |||||
| Intangible assets, net (excluding goodwill) | 20,838 | |||||
| Total noncurrent assets: | 21,159 | |||||
| TOTAL ASSETS: | 18,911,456 | 13,619,145 | 6,924,646 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 2,218,425 | 9,349,662 | 6,413,044 | |||
| Accounts payable | 1,737,463 | 7,843,136 | 2,975,398 | |||
| Accrued liabilities | 480,962 | 1,506,526 | 3,437,646 | |||
| Total current liabilities: | 2,218,425 | 9,349,662 | 6,413,044 | |||
| Noncurrent Liabilities | ||||||
| Liabilities, other than long-term debt | 199,263 | |||||
| Deferred compensation liability, classified | 199,263 | |||||
| Other undisclosed noncurrent liabilities | 5,592 | 516,187 | 1,859,374 | |||
| Total noncurrent liabilities: | 204,855 | 516,187 | 1,859,374 | |||
| Total liabilities: | 2,423,280 | 9,865,849 | 8,272,418 | |||
| Equity | ||||||
| Equity, attributable to parent | 16,488,176 | 3,753,296 | (1,347,772) | |||
| Additional paid in capital | 107,546,433 | 97,590,426 | 79,101,061 | |||
| Accumulated other comprehensive loss | (371,184) | (371,184) | (195,369) | |||
| Accumulated deficit | (90,687,073) | (93,465,946) | (80,253,464) | |||
| Total equity: | 16,488,176 | 3,753,296 | (1,347,772) | |||
| TOTAL LIABILITIES AND EQUITY: | 18,911,456 | 13,619,145 | 6,924,646 | |||
Income Statement (P&L) (USD)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Gross profit: | (557,665) | ||||
| Operating expenses | (16,827,478) | (14,262,733) | (23,379,912) | ||
| Other undisclosed operating income | 557,665 | ||||
| Operating loss: | (16,827,478) | (14,262,733) | (23,379,912) | ||
| Nonoperating income | 19,606,351 | 1,050,251 | 5,317,649 | ||
| Other nonoperating income | 626,184 | 384,903 | 115,525 | ||
| Interest and debt expense | (76,775) | (201,390) | (282,064) | ||
| Income (loss) from continuing operations: | 2,702,098 | (13,413,872) | (18,344,327) | ||
| Other undisclosed net income | 76,775 | 201,390 | 282,064 | ||
| Net income (loss) attributable to parent: | 2,778,873 | (13,212,482) | (18,062,263) | ||
| Other undisclosed net income available to common stockholders, basic | 26,424,964 | 36,124,526 | |||
| Net income (loss) available to common stockholders, diluted: | 2,778,873 | 13,212,482 | 18,062,263 | ||
Comprehensive Income (USD)
| 3/31/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
| Net income (loss): | 2,778,873 | (13,212,482) | (18,062,263) | ||
| Comprehensive income (loss): | 2,778,873 | (13,212,482) | (18,062,263) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (7,450) | ||||
| Comprehensive income (loss), net of tax, attributable to parent: | 2,778,873 | (13,212,482) | (18,069,713) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.